en
Scientific article
English

The vitamin D receptor gene bAt (CCA) haplotype impairs the response to pegylated-interferon/ribavirin-based therapy in chronic hepatitis C patients

Published inAntiviral therapy, vol. 17, no. 3, p. 541-547
Publication date2012
Abstract

Chronic hepatitis C infection is a major cause of end-stage liver disease. Therapy outcome is influenced by 25-OH vitamin D deficiency. To further address this observation, our study investigates the impact of the vitamin D receptor (NR1I1) haplotype and combined effects of plasma vitamin D levels in a well-described cohort of hepatitis C patients.

Keywords
  • Adult
  • Aged
  • Antiviral Agents/therapeutic use
  • Cohort Studies
  • Drug Therapy, Combination
  • Female
  • Genotype
  • Haplotypes/genetics
  • Hepacivirus/drug effects/genetics
  • Hepatitis C, Chronic/drug therapy/genetics/virology
  • Humans
  • Interferons/therapeutic use
  • Male
  • Middle Aged
  • Polyethylene Glycols/therapeutic use
  • Polymorphism, Genetic
  • Receptors, Calcitriol/genetics
  • Ribavirin/therapeutic use
  • Treatment Outcome
  • Vitamin D/blood
Citation (ISO format)
BAUR, Katharina et al. The vitamin D receptor gene bAt (CCA) haplotype impairs the response to pegylated-interferon/ribavirin-based therapy in chronic hepatitis C patients. In: Antiviral therapy, 2012, vol. 17, n° 3, p. 541–547. doi: 10.3851/IMP2018
Main files (1)
Article (Published version)
accessLevelRestricted
Identifiers
ISSN of the journal1359-6535
589views
1downloads

Technical informations

Creation03/26/2013 2:24:00 PM
First validation03/26/2013 2:24:00 PM
Update time03/14/2023 8:09:23 PM
Status update03/14/2023 8:09:23 PM
Last indexation01/16/2024 1:33:16 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack